Leading Cause of blindness has new US & EU Orphan Drug Designation Immunotherapy

14/09/2015 - 2 minutes

TxCell, from Nice (Fr), has been granted EU and US Orphan Drug Designation for its T-cell based therapy for autoimmune uveitis – an eye inflammatory disease responsible of 10-15% legal blindness in developed countries.


TxCell is a spin-off from France’s National Institute for Health and Medical Research (Inserm), with a pipeline including a phase II treatment for Crohn’s disease. Having been developed from its ASTRiA immunotherapy manufacturing platform, the company engineers type 1 T-cells which when administered to the patient, reduce local site inflammation by antigen-triggered immune-suppression, and thus alleviate symptoms of autoimmune conditions.

Such is the case for Col-Treg, TxCell’s second candidate therapy developed to treat autoimmune Uveitis (AU) by targeting the ocular collagen-II antigen. AU is autoimmune swelling of the uvea (the layer between the cornea and inner retina of the eye). It is often seen in those suffering autoimmune disorders such as Crohn’s disease and is considered an ophthalmic emergency.

TxCell plans to move Col-Treg into its first clinical study in 2016,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member